<DOC>
	<DOCNO>NCT00469729</DOCNO>
	<brief_summary>The purpose study determine efficacy safety transplant StemEx® patient certain hematological malignancy . For patient , suggest StemEx® improve upon outcome transplant single , unmanipulated cord blood unit significantly increase number stem/progenitor cell available patient .</brief_summary>
	<brief_title>Efficacy Safety Study StemEx® , Treat Subjects With High Risk Hematologic Malignancies , Following Myeloablative Therapy</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation life-saving procedure patient hematologic malignancy ; yet wide application procedure limited availability suitably Human Leukocyte Antigen ( HLA ) - match donor . Only 30 % patient could benefit procedure HLA-matched sibling . The lengthy search match donor may critically delay transplantation . In addition , far few patient racial minority find suitable HLA-matched donor . Umbilical cord blood ( UCB ) increasingly use alternative source stem cell ; however , use adult adolescent patient limit due insufficient cell dose require satisfactory hematopoietic reconstitution . Gamida Cell - Teva Joint Venture Ltd. engage development StemEx® , expand hematopoietic UCB stem cell graft , potential medicinal product treatment cancer hematological malignancy . The expansion technology enable preferential expansion hematopoietic stem early progenitor cell base finding copper chelators regulate balance self-renewal differentiation stem cell . The multi-national , multi-center Phase II/III clinical study designate evaluate safety efficacy StemEx® enroll approximately 100 subject high-risk hematologic malignancy candidate allogeneic stem cell transplantation ( SCT ) . This study evaluate effect StemEx® overall survival measure overall 100-day mortality . The study consist 4 phase : 1 . Screening phase include subject ' clinical assessment screen test 2 . Conditioning phase include myeloablative treatment prior transplantation procedure 3 . Transplantation post-transplant follow-up phase day 180 4 . Observational phase : survival status follow-up day 730 ( 18 month )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>1 . Clinical diagnosis AML ALL : CR2 subsequent complete remission ( CR ) CR1 highrisk feature relapse &lt; 10 % blast BM circulate blast . 2 . Clinical diagnosis CML : CP1 ( Chronic Phase 1 ) resistant intolerant Gleevec CP2 subsequent CP accelerate phase . 3 . Clinical diagnosis HD : induction failure relapse sensitive last chemotherapy course . 4 . Clinical diagnosis NHL induction failure relapse sensitive last chemotherapy course . 5 . Clinical diagnosis MDS intermediate 2 highrisk IPSS score . 1 . Less twentyone day elapse since subject 's last radiation chemotherapy prior conditioning ( except Hydroxyurea ) . 2 . HIV positive . 3 . Pregnancy lactation . 4 . Uncontrolled bacterial , fungal viral infection . 5 . Subjects sign symptom active central nervous system ( CNS ) disease . 6 . Availability appropriate related willing stem cell donor , HLAmatched 5 6/6 antigen . 7 . Prior allogeneic cell transplant . 8 . Allergy bovine product , may interfere treatment . 9 . Enrolled another clinical trial receive investigational treatment last 30 day , unless approve Sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Tetraethylenepentamine</keyword>
	<keyword>Umbilical Cord Blood Stem Cell Transplantation</keyword>
	<keyword>Hematological Malignancies</keyword>
	<keyword>Acute Lymphoid Leukemia</keyword>
	<keyword>Subjects high-risk hematologic malignancy candidate allogeneic stem cell transplantation</keyword>
</DOC>